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Previous studies indicate that reduced concentrations of circulating high-density
lipoprotein (HDL) particles can be superior to HDL-cholesterol (HDL-C) levels as a
predictor of cardiovascular disease. Measurements of HDL particle numbers, therefore,
bear a potential for the improved assessment of cardiovascular risk. Furthermore,
such measurement can be relevant for the evaluation of novel therapeutic approaches
targeting HDL. Modern in-depth analyses of HDL particle profile may further improve
evaluation of cardiovascular risk. Although clinical relevance of circulating concentrations
of HDL subpopulations to cardiovascular disease remains controversial, the negative
relationship between the number of large HDL particles and cardiovascular disease
suggests that assessment of HDL particle profile can be clinically useful. Reduced mean
HDL size is equally associated with cardiovascular disease in large-scale clinical studies.
Since HDL-C is primarily carried in the circulation by large, lipid-rich HDL particles,
the inverse relationship between HDL size and cardiovascular risk can be secondary
to those established for plasma levels of HDL particles, HDL-C, and large HDL. The
epidemiological data thereby suggest that HDL particle number may represent a more
relevant therapeutic target as compared to HDL-C.
Keywords: high-density lipoprotein, particle number, HDL cholesterol, plasma concentrations, circulating levels,
large HDL, cardiovascular risk, cardiovascular disease, atherosclerosis
The inverse relationship between circulating concentrations of high density lipoprotein (HDL)-
cholesterol (HDL-C) and cardiovascular risk is ﬁrmly established. This relationship is thought
to reﬂect multiple cardioprotective properties of HDL, which primarily include its capacity to
eﬄux cholesterol from peripheral cells but may also involve antioxidative, anti-inﬂammatory, anti-
apoptotic, anti-thrombotic, anti-infectious, and anti-diabetic activities (Camont et al., 2011). Low
levels of HDL-C are frequently accompanied by defective HDL functionality as shown in patients
with established cardiovascular disease and with diﬀerent forms of dyslipidemia (Kontush and
Chapman, 2006b; Riwanto and Landmesser, 2013). Measurements of HDL-C levels are simple,
can easily be performed in a clinical setting and might, therefore, provide an estimate for defective
HDL function.
However, considerable residual risk exists even at high plasma levels of HDL-C, suggesting
that other HDL-associated metrics might provide better assessment of the relationship between
HDL metabolism and cardiovascular disease. Moreover, a series of recent large-scale HDL-C-
raising trials failed to reduce cardiovascular disease, additionally demonstrating limitations of
HDL-C as a therapeutic target. Metrics of HDL functionality represent an obvious alternative to
HDL-C (Hovingh et al., 2015); their reliable assessment is, however, challenging in the clinical
routine, reﬂecting their limited use at present. Other, than HDL-C, biomarkers of HDLmetabolism
frequently employed in the clinic include circulating levels of apolipoprotein A-I (apoA-I, themajor
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HDL protein), concentrations of HDL particles, and mean
HDL size. Several large-scale trials have systematically evaluated
potential clinical value of these biomarkers. The present article
reviews data obtained for the associations between cardiovascular
risk and circulating concentrations (numbers), and mean size of
HDL particles in humans.
Total Number of HDL Particles
Several studies evaluated the relationship of cardiovascular risk
with total number of HDL particles in the circulation (Table 1).
In a nested, case–control, secondary prevention Veterans
Aﬀairs High-Density Lipoprotein Intervention Trial (VA-HIT),
elevated number of HDL particles was a signiﬁcant predictor
of reduced risk of coronary heart disease (CHD) in subjects
treated with gemﬁbrozil or placebo (Otvos et al., 2006). Indeed,
increment in total HDL particle number of 1 standard deviation
(SD) decreased CHD risk by 29% during a 5-year follow-up
(p = 0.0001). By contrast, circulating HDL-C and apoA-I levels
were unable to predict CHD events in this study (risk reduction
of 5%, p= 0.42 and 9%, p= 0.18, respectively).
Similar results were obtained in a primary preventionMultiple
Risk Factor Intervention Trial (MRFIT) of CHD mortality in
men at high risk of CHD (Kuller et al., 2007). In two groups of
middle-aged men who died or did not die of CHD over 18 years
of follow-up, elevated total HDL particle number at baseline
signiﬁcantly reduced CHD death by 50% for the comparison
between the top and the bottom quartiles. As in the VA-HIT
study, levels of HDL-C were not associated with the endpoint
(risk reduction of 0% for the same comparison).
In a case–control European Prospective Investigation into
Cancer and Nutrition (EPIC)-Norfolk study of apparently
healthy men and women, total HDL particle concentration at
baseline was signiﬁcantly diminished in CHD cases relative to
controls (El Harchaoui et al., 2009). As a consequence, HDL
particle concentrations in the top quartile decreased coronary
artery disease (CAD) risk by 50% relative to the bottom quartile
following adjustment for plasma apoB and triglyceride levels.
In a randomized Heart Protection Study (HPS) trial of statin
and antioxidant therapy in high-risk men and women, increment
in total HDL particle number of 1 SD was associated with a
signiﬁcant risk reduction of 11% for major occlusive coronary
events after adjustment for low density lipoprotein (LDL) particle
number (Parish et al., 2012). Associations between cardiovascular
disease and plasma HDL-C and apoA-I levels were slightly
weaker, albeit signiﬁcant (risk reduction of 9% for each of them).
Interestingly, inverse associations of other cardiac events assessed
in this study with biomarkers of HDL metabolism were only
signiﬁcant for HDL particle number (risk reduction of 16%) but
not for HDL-C and apoA-I levels (risk reduction of 6 and 8%,
respectively).
In the Multi-Ethnic Study of Atherosclerosis (MESA) which
evaluated men and women without baseline CHD or lipid
altering therapy, elevated number of HDL particles revealed an
inverse association with both incident CHD events (signiﬁcant
risk reduction of 30% per 1 SD increment in the particle number)
and carotid intima-media thickness (cIMT; Mackey et al., 2012).
These associations were not aﬀected by adjustment for LDL
particle number (risk reduction of 32% per 1 SD increment in
the particle number). Plasma HDL-C concentrations revealed
similar associations with CHD (signiﬁcant risk reduction of
26%) and cIMT, which were, however, markedly attenuated after
adjustment for plasma levels of atherogenic lipoproteins (non-
signiﬁcant risk reduction of 3%).
In a randomized Justiﬁcation for the Use of statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) which enrolled subjects without cardiovascular
disease assigned to either rosuvastatin or placebo, on-treatment
HDL particle number was signiﬁcantly associated with a
composite cardiovascular endpoint in subjects randomized to
the statin (risk reduction of 27% per 1 SD following adjustment
for traditional cardiovascular risk factors; Mora et al., 2013).
Similar associations evaluated for circulating HDL-C and apoA-
I levels were not signiﬁcant (risk reductions of 18 and 14%,
respectively). In subjects randomized to placebo, on-treatment
concentrations of HDL particles, HDL-C, and apoA-I revealed
similar inverse association with the endpoint (signiﬁcant risk
reductions of 19, 25, and 21%, respectively). Interestingly, the
association between on-treatment HDL particle numbers and
cardiovascular endpoint remained signiﬁcant after adjustment
for HDL-C levels in this study.
Particle Numbers of Large vs. Small HDL
HDL particles are highly heterogeneous in structure,
composition, metabolism, and function. Distinct HDL
subpopulations might, therefore, exert diﬀerential eﬀects
on atherosclerosis (Camont et al., 2011). As a consequence,
plasma concentrations of speciﬁc HDL subpopulations can be
hypothesized to reveal stronger associations with cardiovascular
risk as compared to total HDL particle number.
NMR measurements allow distinguishing between large
(size 9.4–14.0 nm), medium (8.3–9.3 nm), and small (7.3–
8.2 nm) HDL particles (Otvos, 2002). Among these HDL
subpopulations, levels of large HDL frequently display inverse
relationships with cardiovascular risk in univariate analyses,
whereas concentrations of small HDL particles typically reveal
positive correlations with the risk (Kuller et al., 2002; Rosenson
et al., 2002; Garvey et al., 2003; Festa et al., 2005; Goﬀ et al., 2005;
Kathiresan et al., 2006; Otvos et al., 2006; Mora et al., 2007, 2009;
van der Steeg et al., 2008; El Harchaoui et al., 2009). Circulating
concentrations of large and small HDL particles as well as those
of large HDL particles and total LDL particles as measured by
NMR are, however, known to be negatively correlated. Such
multiple confounding renders data interpretation controversial,
complicating proper assessment of the relative roles of distinct
HDL subpopulations in cardioprotection (Goﬀ et al., 2005;
Jeyarajah et al., 2006; Mora et al., 2007, 2009; El Harchaoui et al.,
2009).
As a comparison, particle concentrations of HDL
subpopulations can be assessed by the ion mobility assay
which readily separates small (7.7–10.5 nm) and large
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TABLE 1 | Clinical trials, which evaluated relationships between high density lipoprotein (HDL) particle number and cardiovascular disease.
Study Sample size Population Follow-up, years Endpoint Major result Odds ratio
VA-HIT 364 cases
697 controls
Men with established CHD
and low HDL-C randomized
to gemfibrozil or placebo
5.1 MI or CHD death Elevated number of
HDL particles predicted
reduced risk of CHD
0.71 (CI 0.61–0.81) per
1 SD increment
MRFIT 214 cases
214 controls
Middle-aged men who died
or did not die of CHD
matched according to age,
number of MetS
components, and presence
of non-fatal CV event
during the trial
18 CHD death Elevated number of
HDL particles predicted
reduced risk of CHD
death
0.50 (CI 0.26–0.96) for
the top vs. bottom
quartile
EPIC-Norfolk 1003 cases
1885 controls
Apparently healthy men
and women who developed
or did not develop CAD
6 Fatal or non-fatal CAD
event
Elevated number of
HDL particles predicted
reduced risk of CAD
following multiple
adjustment
0.50 (CI 0.37–0.66) for
the top vs. bottom
quartile
HPS Statin, 10,033
Placebo, 9988
High-risk men and women
with CHD randomized to
simvastatin or placebo
5.3 MI, stroke, vascular
procedures, CV death,
hospital admissions for
other cardiac events
Elevated number of
HDL particles was
associated with
reduced risk of
coronary events
following adjustment for
LDL particle number
0.89 (CI 0.85–0.93) per
1 SD increment
MESA 5,598 Men and women without
CHD at baseline or lipid
altering therapy
5.5 CHD events, cIMT Elevated number of
HDL particles was
associated with
reduced risk of incident
CHD events and
decreased cIMT
following adjustment for
low density lipoprotein
(LDL) particle number
0.68 (CI, 0.54–0.85) per
1 SD increment
JUPITER Statin, 5,367
Placebo, 5,519
Men and women free of
cardiovascular disease
randomized to rosuvastatin
(20 mg/day) or placebo
1 First MI, stroke,
hospitalization for
unstable angina, arterial
revascularization, CV
death
Elevated on-treatment
number of HDL
particles was
associated with
reduced CV risk in
subjects randomized to
both the statin and
placebo
Statin, 0.73 (CI
0.57–0.93) per 1 SD
Placebo, 0.81 (CI
0.67–0.97) per 1 SD
CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; cIMT, carotid intima-media thickness; CV, cardiovascular; MetS, metabolic syndrome;
MI, myocardial infarction; SD, standard deviation.
(10.5–14.5 nm) HDL (Musunuru et al., 2009). Such evaluation
reveals comparable associations of small and large particles with
cardiovascular risk (hazard ratios per 1 SD of 0.78 and 0.75,
respectively; Musunuru et al., 2009).
The inverse relationship between particle number of large
HDL and cardiovascular disease is further consistent with data
on plasma levels (as mg apoA-I/dl) of HDL subpopulations
separated by 2D gel electrophoresis. Indeed, circulating
concentrations of large alpha-1 HDL are consistently associated
with reduced cardiovascular risk (Asztalos and Schaefer, 2003a,b;
Asztalos et al., 2003, 2004; Schaefer and Asztalos, 2007a,b). On
the other hand, levels of small HDL particles assessed by this
methodology are frequently elevated in CHD patients (Asztalos
and Schaefer, 2003a,b; Asztalos et al., 2003; Lamon-Fava et al.,
2008). Importantly, the power of large alpha-1 HDL to predict
CHD risk is typically superior to that of HDL-C in these studies
(Asztalos et al., 2003, 2005; Lamon-Fava et al., 2008).
Mean HDL Size
Mean HDL size can be regarded as an integrative measure of
HDL heterogeneity and particle proﬁle. This metric of HDL
metabolism can be assessed by both NMR and ion mobility
measurements and is capable of predicting cardiovascular
risk (Musunuru et al., 2009). An association between mean
HDL size and cardiovascular risk is typically inverse. When
HDL size is used to predict incident cardiovascular disease,
hazard ratios obtained are comparable to those calculated using
HDL-C (Mora et al., 2009) and can be predominantly accounted
for by traditional cardiovascular risk factors (Arsenault
et al., 2009). Consistent with this conclusion, adjustment for
circulating concentrations of apoB and triglycerides abolished
the association between mean HDL size and CAD risk in the
EPIC-Norfolk study, despite reduction in this parameter in cases
relative to controls (El Harchaoui et al., 2009).
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Interestingly, ion mobility measurements allow distinguishing
between two independent components of the association between
HDL size and cardiovascular disease (Musunuru et al., 2009).
The ﬁrst component appears to represent an atherogenic
lipoprotein phenotype, which includes increased concentrations
of triglycerides and small LDL, whereas the second component is
related to elevated levels of small HDL particles.
Intriguingly, very high mean HDL size can be paradoxically
associated with elevated cardiovascular risk as observed in
the EPIC-Norfolk study after multiple adjustment (van der
Steeg et al., 2008); this association resembles those reported
between cardiovascular disease and very high levels of HDL-C as
observed, for example, in the IDEAL study (van der Steeg et al.,
2008).
Effects of Therapeutic Interventions on
HDL Particle Concentrations
Therapeutic interventions aimed at increasing HDL-C
levels, correcting atherogenic dyslipidemia, and reducing
cardiovascular risk may markedly impact HDL particle
concentrations. Thus, both niacin (Kuvin et al., 2006; Le et al.,
2013) and cholesteryl ester transfer protein (CETP) inhibitors
(Brousseau et al., 2005; Ballantyne et al., 2012; Krauss et al., 2012)
potently raise HDL-C and preferentially increase circulating
levels of large HDL, augmenting mean HDL size. By contrast,
eﬀects of niacin and CETP inhibitors on total number of HDL
particles are weaker, consistent with their weaker eﬀects on
plasma concentrations of apoA-I.
Treatment with statins appears to result in comparable
elevations in HDL-C and total HDL particle number (Rosenson
et al., 2009). On the other hand, HDL-C-raising eﬀects of ﬁbrates
are typically accompanied by preferential elevation of circulating
levels of small HDL (Otvos et al., 2006).
Concluding Remarks
Available data reveal that diminished HDL particle number can
be superior to reduced HDL-C levels in terms of cardiovascular
risk prediction. This conclusion is supported by the results of the
large-scale VA-HIT, MRFIT, HPS, MESA, and JUPITER trials.
Measurements of circulating concentrations of HDL particles
can, therefore, be useful to improve clinical assessment of
cardiovascular risk. This approach can also contribute to the
evaluation of novel HDL-targeted therapies, which include CETP
inhibitors, peroxisome proliferator-activated receptor (PPAR)
activators, and reconstituted HDL.
Further improvement in the evaluation of cardiovascular risk
can be provided by in-depth analyses of the HDL particle proﬁle
(Mallol et al., 2015; Matyus et al., 2015). Although clinical
relevance of circulating concentrations of HDL subpopulations
needs to be ﬁrmly established (Rosenson et al., 2011), the negative
association between the number of large HDL particles and
cardiovascular risk suggests that clinical evaluation of the HDL
particle proﬁle can be useful.
Diminished mean HDL size represents another biomarker of
HDL metabolism associated with cardiovascular disease in large-
scale clinical studies. However, available data indicate that this
relationship is secondary to those established for plasma levels
of HDL particles, HDL-C and large HDL; indeed, HDL-C is
primarily carried in the circulation by large, buoyant, lipid-rich
HDL.
The epidemiological data thereby suggest that HDL particle
number can be superior to HDL-C as a therapeutic target.
This conclusion is consistent with the capacity of all HDL
particles to exert a variety of atheroprotective biological activities,
reﬂecting a wide spectrum of molecular protein, and lipid
species present in HDL (Davidson et al., 2009; Heinecke, 2009;
Gordon et al., 2010a,b; Camont et al., 2013; Shah et al., 2013).
High compositional heterogeneity of HDL directly results in
functional heterogeneity amongHDL particles, with small, dense,
and protein-rich HDL typically displaying potent biological
activities (Kontush and Chapman, 2006a; Camont et al., 2011,
2013). The relative importance of diﬀerent biological activities
of HDL for atheroprotection remains presently unclear, raising
a question of the proper evaluation of HDL function in vitro.
Measurement of any individual HDL activity will obviously
provide only limited information on all the aspects of the
functionality of the circulating HDL pool. Evaluation of total
number of circulating HDL particles may provide a surrogate
biomarker reﬂecting anti-atherogenic HDL function, assuming
a proportional association between the two. This hypothesis
will require rigorous assessment in clinical and epidemiological
studies of HDL-targeted therapies, which have failed to provide
unequivocal data in this regard up to now.
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